Research Analysts’ Weekly Ratings Changes for Ambrx Biopharma (AMAM)

Several analysts have recently updated their ratings and price targets for Ambrx Biopharma (NYSE: AMAM):

  • 1/16/2024 – Ambrx Biopharma had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $28.00 price target on the stock.
  • 1/12/2024 – Ambrx Biopharma had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 1/10/2024 – Ambrx Biopharma had its “market perform” rating reaffirmed by analysts at JMP Securities.
  • 1/9/2024 – Ambrx Biopharma was downgraded by analysts at B. Riley from a “buy” rating to a “neutral” rating. They now have a $28.00 price target on the stock, up previously from $26.00.
  • 12/18/2023 – Ambrx Biopharma had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 11/29/2023 – Ambrx Biopharma had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $15.00 price target on the stock.

Ambrx Biopharma Trading Down 0.2 %

NYSE:AMAM opened at $27.74 on Wednesday. Ambrx Biopharma Inc. has a 1-year low of $1.28 and a 1-year high of $28.15. The company’s fifty day moving average price is $16.14 and its 200-day moving average price is $13.73.

Insider Activity at Ambrx Biopharma

In related news, CFO Sonja Nelson sold 12,778 shares of the firm’s stock in a transaction on Friday, October 27th. The shares were sold at an average price of $9.82, for a total transaction of $125,479.96. Following the sale, the chief financial officer now owns 130,079 shares in the company, valued at $1,277,375.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Ambrx Biopharma news, CEO Daniel J. O’connor sold 50,012 shares of the stock in a transaction on Friday, October 27th. The shares were sold at an average price of $9.82, for a total transaction of $491,117.84. Following the transaction, the chief executive officer now directly owns 342,845 shares of the company’s stock, valued at $3,366,737.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Sonja Nelson sold 12,778 shares of the stock in a transaction on Friday, October 27th. The shares were sold at an average price of $9.82, for a total transaction of $125,479.96. Following the transaction, the chief financial officer now directly owns 130,079 shares in the company, valued at $1,277,375.78. The disclosure for this sale can be found here. 0.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ambrx Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of AMAM. Darwin Global Management Ltd. increased its position in Ambrx Biopharma by 49.0% during the first quarter. Darwin Global Management Ltd. now owns 11,304,573 shares of the company’s stock worth $100,837,000 after purchasing an additional 3,720,084 shares during the last quarter. Cormorant Asset Management LP increased its position in shares of Ambrx Biopharma by 13.1% during the second quarter. Cormorant Asset Management LP now owns 9,616,155 shares of the company’s stock valued at $158,282,000 after acquiring an additional 1,116,155 shares during the last quarter. FMR LLC increased its position in shares of Ambrx Biopharma by 0.8% during the second quarter. FMR LLC now owns 3,857,679 shares of the company’s stock valued at $10,223,000 after acquiring an additional 32,320 shares during the last quarter. Federated Hermes Inc. acquired a new stake in shares of Ambrx Biopharma during the third quarter valued at about $27,552,000. Finally, Holocene Advisors LP acquired a new stake in shares of Ambrx Biopharma during the second quarter valued at about $15,040,000. 77.28% of the stock is owned by hedge funds and other institutional investors.

Ambrx Biopharma Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2.

See Also

Receive News & Ratings for Ambrx Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.